Tevogen Bio Holdings: Buy Rating, PT Raised to $10 by D. Boral Capital

Tevogen Bio Holdings: Buy Rating, PT Raised to $10 by D. Boral Capital

Title: Tevogen Bio Holdings: Buy Rating, PT Raised to $10 by D. Boral Capital

Tevogen Bio Holdings Inc. (TVGN), a clinical-stage specialty immunotherapy company, has received a "Buy" rating with a price target (PT) of $10 from D. Boral Capital, according to a recent report [2]. The rating comes as the company announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion [1].

Tevogen Bio specializes in developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious diseases and cancers. The company's pipeline includes several promising candidates, such as TVGN 489 for the treatment of SARS-CoV-2 infection in various patient populations, TVGN 920 for cervical cancer prevention, TVGN 930 for EBV-associated lymphomas, and TVGN 960 for mouth and throat cancer [3].

The company's unique drug development model, which emphasizes speed and cost efficiency, positions it to serve as a blueprint for sustainable medical innovation. Tevogen Bio's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation [1].

The forward-looking statements in the press release highlight the potential benefits of Tevogen Bio's product candidates for the treatment of infectious diseases, cancer, and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID. However, these statements are subject to various risks and uncertainties, including the need for additional capital, regulatory approvals, and competition [1].

Tevogen Bio's stock has shown above-average performance over the past 5 years, with a sharpe ratio of -0.1932 compared to the peer average of -0.2540 [2]. Analysts are estimating a 12-month price target range of $10.00 - $10.00 with an average of $10.00, indicating a high level of consensus on the company's future growth potential [2].

References
[1] https://www.morningstar.com/news/globe-newswire/9510185/repeat-tevogen-bio-specialty-care-reports-top-line-revenue-forecast-of-nearly-1-billion-in-launch-year-and-cumulative-5-year-estimate-between-18-billion-and-22-billion
[2] https://www.benzinga.com/quote/TVGN/report
[3] https://www.stocktitan.net/news/TVGNW/repeat-tevogen-bio-specialty-care-reports-top-line-revenue-forecast-t441sv8f8udo.html